Mundipharma International welcomes positive phase III efficacy findings for Invokana® (canagliflozin) in type 2 diabetes patients with chronic kidney disease

Jul 20 2018

INFORMATION FOR EUROPEAN MEDICAL/TRADE MEDIA ONLY| PDF iconDownload PDF